OpenText Scales U.S. Medical Device EDI Networks as Market Climbs from USD 4.3 Billion in 2026 to USD 14.0 Billion by 2036 at 12.5% CAGR

ROCKVILLE, MARYLAND , August 6, 2026 - The Medical Devices Electronic Data Interchange Market reached USD 3.8 billion in 2025 and is valued at USD 4.3 billion in 2026. Demand is projected to increase to USD 14.0 billion by 2036, recording a 12.5% CAGR from 2026 to 2036 as medical device manufacturers, distributors and healthcare buyers automate recurring trading-partner transactions and expand cloud-based partner connectivity across order, shipment, inventory and compliance workflows.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/report/medical-devices-electronic-data-interchange-market

Key Findings

Software holds 68% share in 2026 and carries a USD 9.6 billion absolute opportunity by 2036.
Cloud-Based deployment accounts for 72% share in 2026.
Supply Chain Transactions represent 38% share in 2026.
Medical Device Manufacturers contribute 45% share in 2026.
Large Enterprises account for 65% share in 2026.
South Korea leads country CAGRs at 13.55% (2026-2036).

Growth Drivers

Purchase order, order confirmation, advance shipping notice and invoice automation reduces repetitive entry across manufacturers, distributors, logistics providers and hospital procurement teams.
UDI and device master-data requirements raise the commercial cost of inconsistent identifiers, packaging hierarchies, lot fields and partner-specific product records.
Cloud ERP and warehouse modernization creates new integration points while EDI remains necessary for partners that cannot move to APIs at the same pace.
Recall readiness and inventory control increase the value of clean shipment, lot, serial and location data across the device supply chain.
Order-to-cash and procure-to-pay automation, UDI-linked product master data governance, and ERP modernization with partner onboarding are the primary drivers, with relevance strongest in the USA, UK, Germany, South Korea, Australia, Canada and Japan over 2026-2036.

Segment Analysis by Component, Deployment, Transaction Type, End User and Enterprise Size

Component

Software is projected to hold 68% share in 2026 because mapping, validation, partner profiles, monitoring and document orchestration sit at the center of recurring EDI operations. Medical device companies also need connectors to ERP, warehouse, transportation and procurement systems so that EDI messages create usable business records. Services remain important for implementation and managed operations.

Deployment

Cloud-Based deployment is anticipated to account for 72% share in 2026 because multi-enterprise connectivity benefits from scalable infrastructure, managed updates and faster partner onboarding. Public cloud supports standardized use cases; hybrid cloud allows retention of sensitive or validated systems. On-premise remains relevant where local change control outweighs migration speed.

Transaction Type

Supply Chain Transactions are forecast to represent 38% share in 2026 because purchase orders and order confirmations establish the commercial commitment between hospitals, distributors and device suppliers. These messages determine item, quantity, delivery location and timing before shipment and payment records. Advance shipping notices and inventory synchronization expand visibility; UDI reporting and regulatory filings serve narrower compliance workflows.

End User

Medical Device Manufacturers are expected to account for 45% share in 2026 because they sit at the point where product master data, regulatory identifiers, available inventory and customer commitments must agree. They exchange orders and shipment data with distributors, logistics providers, hospitals and group purchasing organizations.

Enterprise Size

Large Enterprises are projected to hold 65% share in 2026 because global device portfolios create high partner counts, multiple ERP instances, regional data rules and continuous onboarding work. They require centralized governance for certificates, protocols, mapping versions and service-level monitoring.

Country-Level Growth Comparison

Country

CAGR (2026-2036)

One-line commercial condition

South Korea

13.55%

UDI product data and distribution transaction reporting via Ministry of Food and Drug Safety system

USA

12.93%

Mature hospital-distributor-manufacturer networks supported by FDA GUDID and X12 transactions

Canada

12.56%

Health Canada mandatory Common Electronic Submission Gateway and regulatory enrolment from April 2026 plus provincial procurement modernization

UK

12.29%

Great Britain MHRA registration plus Northern Ireland EUDAMED obligations from May 2026

Australia

12.22%

Mandatory UDI for higher-risk devices from July 2026 and AusUDID data maintenance

Germany

12.08%

EU MDR/IVDR obligations, mandatory EUDAMED modules from May 2026 and cross-border distribution

Japan

11.69%

Mandatory device identification codes, hospital traceability programs and controlled enterprise integration

Competitive Landscape

Key companies include OpenText Corporation; SPS Commerce, Inc.; TrueCommerce Inc.; IBM Corporation; Oracle Corporation; SAP SE; Cleo Communications US LLC; Boomi LP; MuleSoft (Salesforce); and Babelway (Tradeshift).

OpenText Corporation anchors large-scale B2B network connectivity, EDI and API exchange, managed services and ERP integration.
SPS Commerce and TrueCommerce focus on supplier-facing EDI and recurring purchase order, shipment and invoice workflows.
IBM supports complex high-volume B2B operations through Sterling.
Oracle and SAP connect partner exchange with broad enterprise application estates.
Cleo and Boomi combine EDI with cloud integration and partner management.
MuleSoft and Babelway support integration-led architectures coordinating APIs, applications and trading-partner messages.

Recent Developments and Regulatory Context

Health Canada made the Common Electronic Submission Gateway and regulatory enrolment process mandatory for medical device manufacturers from April 2026.
UK Northern Ireland follows mandatory EUDAMED use for covered modules from May 2026; Great Britain registration continues with MHRA.
Australia introduced mandatory UDI requirements for higher-risk devices from July 2026 and operates the Australian UDI Database linked to ARTG inclusions.
EU mandatory use of four EUDAMED modules from May 2026 under MDR and IVDR.
FDA GUDID provides the U.S. reference catalog for device identifiers; X12 transaction sets support purchase order, acknowledgment and ship-notice exchange.
South Korea's Ministry of Food and Drug Safety operates the UDI traceability system.
Japan requires identification codes on medical device packaging.

Restraints

Mapping and master-data inconsistency: the same device can appear under different catalog numbers, units of measure or packaging hierarchies, causing transaction exceptions and receiving errors (all regions, 2026-2036).
Legacy ERP validation and change control: regulated manufacturers require formal testing and approval for each map or interface change, lengthening implementation cycles (Japan, Germany and large manufacturers).
Third-party cybersecurity and service concentration: cloud EDI places critical order and shipment traffic on external infrastructure, prompting evaluation of access control, encryption, resilience, incident response and supplier risk (cloud deployments globally).

How to Choose

Assess partner-governance capability: evaluate mapping accuracy, partner profiles, acknowledgments and exception handling across the full trading-partner set.
Verify UDI and product-master integration: confirm the platform maintains consistent device identifiers, packaging hierarchies, lot fields and regulatory database connectors (GUDID, EUDAMED, AusUDID, South Korea system).
Require ERP, warehouse and procurement connectivity: ensure EDI messages create usable business records rather than isolated files, with support for both EDI and API coexistence.
Evaluate cloud scalability and managed operations: prioritize platforms that support multi-enterprise onboarding, monitoring, certificate management and hybrid deployment where validated systems must remain controlled.
Examine change-control and audit evidence: confirm disciplined processes that document every mapped field reaching the correct ERP, warehouse and compliance workflow.
Review cybersecurity and continuity controls: assess encryption, access control, resilience, incident response and supplier-risk posture before consolidating partner traffic.

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/medical-devices-electronic-data-interchange-market

Report Scope

The report covers revenue from EDI software platforms, B2B integration software, implementation services and managed EDI services within Component, Deployment, Transaction Type, End User and Enterprise Size categories for 2026-2036. It includes transaction translation, mapping, validation, routing, acknowledgments, partner onboarding, monitoring and enterprise-application integration. Scope excludes medical device sales, freight, hardware, general ERP licences, claims-only healthcare EDI, patient-record exchange and stand-alone consulting not tied to EDI implementation or managed operations.

Explore More Related Studies Published by Fact.MR Research

Acinetobacter Pneumonia Therapeutics Market https://www.factmr.com/report/acinetobacter-pneumonia-therapeutics-market

AI Drug Repurposing Market https://www.factmr.com/report/ai-drug-repurposing-market

Drug Reference Apps Market https://www.factmr.com/report/drug-reference-apps-market

Erythropoietin (EPO) Drugs Market https://www.factmr.com/report/erythropoietin-epo-drugs-market

Solid Tumor Testing Market https://www.factmr.com/report/solid-tumor-testing-market

Flag: The quote attributed to analyst S.N. Jha is sourced directly from published commentary on the report page and requires standard PR media sign-off before official press wire dissemination.

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.